Cardiac Stent Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Cardiac stent plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹5.4 crore - ₹94 crore CapEx this DPR captures:

• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The Indian cardiac stent manufacturing sector is characterized by a dual structure of organized and largely non-existent unorganized segments. The organized sector is dominated by large multinational corporations and major domestic manufacturers operating licensed, high-capacity production plants equipped with compliance-driven cleanrooms. The unorganized or informal sector is virtually non-existent for primary stent manufacturing due to the rigorous licensing requirements and complex Class III medical device regulatory framework, which creates a high barrier to entry and effectively limits primary production to formally registered entities.</p><p>India remains critically import-dependent, with more than 80% of critical cardiac implantables, including advanced drug-eluting stents, sourced from international suppliers.

This substantial import dependency creates a compelling case for domestic manufacturing expansion. The key manufacturing hub in India is Gujarat, particularly the Vapi region, which serves as the headquarters for Meril Life Sciences Pvt. Ltd., a leading domestic stent manufacturer.

Sahajanand Medical Technologies (SMT), established in 1998 and headquartered in Surat, Gujarat, has emerged as India's largest domestic cardiac stent manufacturer with significant international market reach, while Translumina Therapeutics represents another key domestic player in the coronary stent space.</p><p>Demand is being driven by the rising global prevalence of coronary artery disease, accelerated by lifestyle-related health conditions and an expanding aging demographic. Buyers and patients are showing strong preference for percutaneous coronary interventions over open-heart coronary artery bypass graft surgeries due to shorter recovery times, further fueling stent demand. Additionally, drug-eluting stents and advanced cobalt-chromium or platinum-chromium alloy platforms are seeing heightened demand as the standard of care continues to evolve.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>Modern cardiac stent manufacturing in India leverages a sophisticated combination of laser micromachining, advanced metallurgy, and precision automation technologies. The primary manufacturing technology centers on high-precision fiber laser cutting systems, which are equipped with fixed cutting heads, lathe-style configurations, and high-accuracy linear and rotary stages to shape intricate stent geometries from medical-grade tube stock. The adoption of 5D precession scanning represents a significant technological advancement, eliminating limitations associated with traditional fixed-cutting heads by enabling ultra-precise control over cut kerfs, substantially reducing heat-affected zones, and delivering cleaner tube-stock processing outcomes critical for implant safety.</p><p>Ultrafast laser systems, specifically industrial ultrafast fiber lasers, are integrated into advanced production lines to further enhance cutting precision and surface quality.

These systems work in conjunction with electropolishing, balloon-mounting, and drug-coating processes to produce both bare-metal stents and drug-eluting stents. The raw material palette is dominated by specialized medical-grade alloys: Cobalt-Chromium (CoCr) alloys such as L605 (Co-20Cr-15W-10Ni), Nickel-Titanium (Nitinol), and 316L Stainless Steel, each selected for specific biocompatibility, radial strength, and flexibility characteristics suited to different clinical applications.</p><p>Major international players have embedded sustainability targets into their manufacturing operations. Abbott Laboratories, under its 2030 Sustainability Plan, targets a 30% reduction in absolute Scope 1 and Scope 2 carbon emissions from a 2018 baseline, aligned with Science Based Targets initiative guidelines.

Boston Scientific Corporation achieved 100% renewable electricity supply at key manufacturing and distribution sites in 2024 and reported a 47% reduction in emissions, demonstrating how environmental compliance is becoming a competitive differentiator in global stent supply chains and a relevant consideration for any new plant investment.</p>

The project's CapEx range of ₹5.4 crore to ₹94 crore accommodates three distinct operating models warranting differentiated financing structures. Entry-scale facilities (₹5.4-15 crore) targeting 30,000-50,000 stents annually through single-product lines merit 70:30 debt-equity structuring with term loans from SIDBI's Healthcare and Medical Devices Fund or ICICI Bank's EMRG product. PMEGP loans up to ₹50 lakh are applicable for micro-scale operations classified under MSME Udyam registration. Mid-scale projects (₹15-45 crore) with 100,000-200,000 unit capacity should pursue 60:40 leverage through consortium financing led by State Bank of India (largest healthcare lending book among Indian public sector banks) or HDFC Bank's Medical Equipment Finance vertical. PLI Scheme for Medical Devices benefits include 5% incentive on incremental sales for five years post commencement, applicable from year two and capable of covering 12-18% of project payback obligation. Large-scale integrated facilities (₹45-94 crore) warrant 55:45 debt-equity with term facilities from Exim Bank's export financing window and IDBI Bank's healthcare project finance desk, supplemented by state industrial development corporation incentives in Gujarat (25% capex subsidy under Pharma Policy 2023), Maharashtra (50% stamp duty exemption in MIHAN zone), or Tamil Nadu (75% power tariff subsidy for first five years). Working capital requirements reflect a 45-60 day receivable cycle dominated by hospital and institutional customers with tender payment terms. Inventory of raw materials (30-45 days), work-in-progress (15-20 days for multi-stage stent processing), and finished goods (20-30 days) generates combined working capital cycle of 95-120 days, warranting working capital limits of ₹4-12 crore for mid-scale operations. Debt service coverage ratio benchmarks at 1.35x minimum for bank appraisal, with interest coverage ratio above 2.1x across base case projections.

<p>Raw material supply chain constraints represent the most critical operational risk for cardiac stent manufacturers in India. The sector relies heavily on imported specialized medical-grade alloys, particularly Cobalt-Chromium (CoCr) and Nickel-Titanium (Nitinol), which creates exposure to foreign exchange volatility, international supply disruptions, and potential import tariff changes. Any disruption to the supply of these critical raw materials can halt production lines, as there are limited domestic sources capable of producing medical-grade alloy tubing meeting the stringent specifications required for Class D implantable devices.</p><p>Regulatory price controls impose structural margin constraints on all market participants.

The NPPA's price cap of INR 38,933.14 per unit for drug-eluting stents and INR 10,692.69 per unit for bare metal stents, effective as of April 2025, limits the pricing flexibility available to manufacturers. Domestic production costs of approximately INR 8,000 per unit for DES, combined with regulatory compliance costs for Class D devices, cleanroom maintenance, and quality assurance, compress the margin envelope. The February 2017 price cap event demonstrated the market's vulnerability to regulatory intervention, with a 59% year-on-year market impact that restructured the competitive landscape overnight.

Any future NPPA adjustments using WPI-linked revision mechanisms could further squeeze returns.</p><p>Capital intensity and project execution risks are substantial. Sahajanand Medical Technologies' INR 250 crore investment in its Telangana plant, with INR 130 crore deployed in the first phase alone, illustrates the significant capital requirements for a commercially viable stent manufacturing facility. Landed costs for imported drug-eluting stents starting at approximately INR 5,000 per unit, combined with total trade markups historically ranging from 375% to 450% before regulatory caps, reflect the complex cost economics that new entrants must navigate.

Greenfield plant development requires Class D cleanroom infrastructure, CDSCO manufacturing licensing, extensive quality systems validation, and skilled personnel recruitment, all contributing to long gestation periods before revenue generation begins.</p><p>Competitive threats from alternative treatment modalities, including drug-coated balloons and established coronary artery bypass graft surgical procedures, create a dynamic where stent volumes could face substitution pressure if clinical evidence favors competing technologies. Additionally, the market faces demand volatility tied to healthcare policy shifts, insurance coverage changes, and macroeconomic factors affecting elective procedure volumes. The highly regulated nature of Class D device manufacturing means any compliance failure, quality recall, or CDSCO enforcement action can result in severe reputational damage, production shutdown, and substantial financial losses, representing an ongoing operational risk that requires sustained investment in quality infrastructure.</p>